| Treatment |  | ||||||
---|---|---|---|---|---|---|---|---|
Characteristics | 2 mg/kg (n = 53) | 4 mg/kg (n = 54) | 8 mg/kg (n = 52) | 2 mg/kg + MTX (n = 52) | 4 mg/kg + MTX (n = 49) | 8 mg/kg + MTX (n = 50) | MTX (n = 49) | All groups (n = 359) |
Age (years) | 52.2 | 49.3 | 50.1 | 49.2 | 50.2 | 50.1 | 50.9 | 50.3 |
Sex (male/female) | 9/44 | 13/41 | 14/38 | 7/45 | 12/37 | 11/39 | 11/38 | 77/282 |
Duration of RA (years) | 9.19 | 9.79 | 9.21 | 9.33 | 7.82 | 10.62 | 11.24 | - |
TJC (28) | 15 | 15 | 15 | 15 | 13 | 15 | 16 | 15 |
SJC (28) | 11 | 11 | 12 | 11 | 11 | 11 | 12 | 11 |
ESR (mm/hour) | 39a | 41 | 39b | 45c | 40 | 39d | 43 | 41 |
CRP (mg/l) | 26a | 19 | 22b | 28c | 31 | 24d | 32 | 27 |
DAS28 | 6.48a | 6.55 | 6.43b | 6.58c | 6.34 | 6.47d | 6.75 | Â |
RF positive (n) | 44 | 39 | 43 | 46 | 38 | 40 | 47 | Â |